24/7 Customer Service (800) 927-7671

Materialise CEO on medical 3D Printing

by • May 5, 2016 • No Comments


Materialise incorporates additional than 25 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, which include healthcare, car, aerospace, art and create, and consumer goods, to create new 3D printing applications which aim to manufacture the world a advantageous and healthier place.

Fried Vancraen, CEO of Materialise – not long ago called upon industry stakeholders to come to an agreement for a common standard for measuring the clinical, economical and patient benefits of medical 3D printing.


Materialise can be leading this on-going initiative as the founding sponsor of the ‘Building Evidence for 3D Printing Applications in Medicine’ event hosted by SME. It is becoming increasingly clear which 3D printed anatomical models, guides and implants can be part of the next of patient treatment, for additional than just difficult procedures.

But, unlike the mass-produced medical device industry, adoption of 3D printing needs additional generally accepted measurement standards. The application of consistent and deplete evidence gathering methodologies across the industry may significantly foster the adoption of 3D Printing use in the healthcare sector.

A unified initiative addressing the clinical measurement challenge can additional enhance the healthcare industry’s confidence in the clinical benefits of medical 3D Printing. A set of globally accepted guidelines adopted by the leading medical 3D printing industry players can convince key stakeholders like physicians, hospitals and policy manufacturers to accelerate adoption of the innovation.

What is additional, governmental bodies and insurance companies are additional most likely to be open to which include medical 3D printing as part of their approved list of medical procedures and devices, leaving patients with the opportunity to leverage the most solutions which innovation has to contribute for their care.

“There have been several initiatives aimed at properly measuring and validating the clinical benefits of medical 3D Printing, but all have suffered of a lack of coordination and agreed-upon research methodologies,” noted Vancraen.

“The fact is, we can just be successful if we take an evidence-based approach across the industry, acting in concert with a set of protocols, methodologies and measurement guidelines. With the proper scientific rigor, our ambition of gaining widespread acceptance of medical 3D Printing can be accomplished additional swiftly, and the patients whom we aim to assist can benefit the most.”

Meeting the complex criteria of evidence-based medicine may not just accelerate the adoption of medical 3D Printing but it may in addition benefit the lives of so most patients who have no access to the awe-inspiring health benefits afforded by medical 3D Printing at present. Materialise is committing to take a leadership role in what has to be an industry-wide initiative to start studying and createing a new evidence-based approach which can factor in all key perspectives: economical, clinical, engineering and patient.

“The goal is nothing short of establishing the groundwork for making solid clinical evidence on 3D printed medical applications, which include anatomical models, patient-specific guides and implants,” introduced Vancraen. “Anything short of this can slow down the wonders of medical 3D Printing of becoming on the market to patients and medical professionals the world over.”


Latest posts

by admin • March 5, 2017